ArticleESC heart failure2023
Rising arterial stiffness with accumulating comorbidities associates with heart failure with preserved ejection fraction.
Article in ESC heart failure, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- The association between pulse wave velocity and heart failure: a systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2024Pooled it
- Association of Cardiac MRI-derived Aortic Stiffness with Early Stages and Progression of Heart Failure with Preserved Ejection Fraction.Radiology. Cardiothoracic imaging · 2024Trial
- Effects of sympathomodulation on pulse wave properties in heart failure with preserved ejection fraction.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Beyond Blood Pressure: Arterial Stiffness as a Hemodynamic and Neuroadrenergic Axis Linking Hypertension, Cardiac Remodeling, and Heart Failure.Life (Basel, Switzerland) · 2026Review
- Intensive blood pressure control in heart failure with preserved ejection fraction: a symptom-modifying strategy.Heart failure reviews · 2026Review
- Vascular Protection of Poly(ADP-ribose) Polymerase Inhibitors in the Combination Therapy With Vascular Endothelial Growth Factor Signaling Pathway Inhibitors.Reviews in cardiovascular medicine · 2026Review
- Heart Failure in the Modern Era: A Narrative Overview of Recent Research from 2022-2025.Journal of cardiovascular development and disease · 2025Review
- Hypertensive acute heart failure: a critical perspective on definition, epidemiology, pathophysiology, and prognosis-a narrative review: a joint session with the Romanian Society of Cardiology (part II).Heart failure reviews · 2025Review
- Central Adiposity or Hypertension: Which Drives Heart Failure With a Preserved Ejection Fraction?Journal of the American College of Cardiology · 2025Review
- Article
- State of precision medicine for heart failure with preserved ejection fraction in a new therapeutic age.ESC heart failure · 2025Review
- Unraveling Heart Failure Phenotypes: A Systematic Review and Meta-analysis of Peak Oxygen Uptake and Its Determinants.CJC open · 2025Review
- Macrophage NLRP3-dependent IL-1β production contributes to aortic fibrosis in heart failure with preserved ejection fraction.Acta biochimica et biophysica Sinica · 2024Article
- Exploring the Relationship Between Ejection Fraction, Arterial Stiffness, NT-proBNP, and Hospitalization Risk in Heart Failure Patients.Diagnostics (Basel, Switzerland) · 2024Article
- Inversion of Left Ventricular Axial Shortening: In Silico Proof of Concept for Treatment of HFpEF.Bioengineering (Basel, Switzerland) · 2024Article
- The Stiffness of the Ascending Aorta Has a Direct Impact on Left Ventricular Function: An In Silico Model.Bioengineering (Basel, Switzerland) · 2024Article
- Novel Strategies in Diagnosing Heart Failure with Preserved Ejection Fraction: A Comprehensive Literature Review.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2024Review
- Rising arterial stiffness with accumulating comorbidities associates with heart failure with preserved ejection fraction.ESC heart failure · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
aimsComorbidities play a significant role towards the pathophysiology of heart failure with preserved ejection fraction (HFpEF), characterized by abnormal macrovascular function and altered ventricular-vascular coupling. However, our understanding of the role of comorbidities and arterial stiffness in HFpEF remains incomplete. We hypothesized that HFpEF is preceded by a cumulative rise in arterial stiffness as cardiovascular comorbidities accumulate, beyond that associated with ageing. METHODS AND
resultsArterial stiffness was assessed using pulse wave velocity (PWV) in five groups: Group A, healthy volunteers (n = 21); Group B, patients with hypertension (n = 21); Group C, hypertension and diabetes mellitus (n = 20); Group D, HFpEF (n = 21); and Group E, HF with reduced ejection fraction (HFrEF) (n = 11). All patients were aged 70 and above. Mean PWV increased from Groups A to D (PWV 10.2, 12.2, 13.0, and 13.7 m/s, respectively) as vascular comorbidities accumulated independent of age, renal function, haemoglobin, obesity (body mass index), smoking status, and hypercholesterolaemia. HFpEF exhibited the highest PWV and HFrEF displayed near-normal levels (13.7 vs. 10 m/s, P = 0.003). PWV was inversely related to peak oxygen consumption (r = -0.304, P = 0.03) and positively correlated with left ventricular filling pressures (E/e') on echocardiography (r = -0.307, P = 0.014).
conclusionsThis study adds further support to the concept of HFpEF as a disease of the vasculature, underlined by an increasing arterial stiffness that is driven by vascular ageing and accumulating vascular comorbidities, for example, hypertension and diabetes. Reflecting a pulsatile arterial afterload associated with diastolic dysfunction and exercise capacity, PWV may provide a clinically relevant tool to identify at-risk intermediate phenotypes (e.g. pre-HFpEF) before overt HFpEF occurs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.